These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9124194)

  • 1. Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
    Baldini E; Tibaldi C; Lencioni M; Giannessi P; Evangelista G; Roncella M; Spinelli C; Meucci C; da Prato M; Conte P
    Am J Clin Oncol; 1997 Apr; 20(2):169-72. PubMed ID: 9124194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
    Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
    Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
    Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
    Mattioli R; Gridelli C; Castellanos J; Duque A; Falcone A; Mansutti M; Bacon P; Lawrinson S; Skacel T; Casas A
    Clin Transl Oncol; 2009 Dec; 11(12):842-8. PubMed ID: 20045791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ; Lee-Ma A; Troxell LS; Chan J
    Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
    Hofmann M; Mahlke M; Casper F; Brockerhoff P
    Zentralbl Gynakol; 1995; 117(6):314-6. PubMed ID: 7544054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer.
    Budd GT; Atiba J; Silver RT; Palmer G; Armstrong S; Otto K; Presant C
    J Cancer Res Clin Oncol; 1999; 125(8-9):500-4. PubMed ID: 10480343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
    Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Elling D
    Br J Cancer; 2006 May; 94(9):1237-44. PubMed ID: 16622463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
    Fornasiero A; Ghiotto C; Daniele O; Favaretto AG; D'Amanzo P; Ziade A
    Tumori; 2001; 87(4):223-8. PubMed ID: 11693799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
    Fumoleau P; Chauvin F; Namer M; Bugat R; Tubiana-Hulin M; Guastalla JP; Delozier T; Kerbrat P; Devaux Y; Bonneterre J; Filleul A; Clavel M
    J Clin Oncol; 2001 Feb; 19(3):612-20. PubMed ID: 11157010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A; Solal-Celigny P; Hoskin P; Taylor K; McMillan A; Forstpointner R; Bacon P; Renwick J; Hiddemann W;
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
    Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Cufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ;
    J Clin Oncol; 2003 Mar; 21(5):843-50. PubMed ID: 12610183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.